---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-049347"
form_type: "8-K"
ticker: "CTOR"
cik: "0001851484"
company_name: "CITIUS ONCOLOGY, INC."
filed_at: "2026-04-29T23:59:59+00:00"
generated_at: "2026-05-15T02:23:49.835059+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Citius Oncology ships first international LYMPHIR order to Europe via NPPs

## Summary
- Initial shipment of LYMPHIR (denileukin diftitox-cxdl) to Europe through regional distribution partner.
- Access via Named Patient Programs (NPPs) in local countries; no EMA marketing authorization.
- LYMPHIR FDA-approved Aug 2024 for relapsed/refractory CTCL; US commercial launch in Dec 2025.
- Company continues US launch with progress on formulary access, payer coverage, and physician engagement.
- CEO Leonard Mazur cites commitment to expanding patient access beyond the US.

## SEC filing metadata
- accession: 0001213900-26-049347
- form_type: 8-K
- ticker: CTOR
- cik: 0001851484
- company_name: CITIUS ONCOLOGY, INC.
- filed_at: 2026-04-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1851484/000121390026049347/0001213900-26-049347-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1851484/000121390026049347/ea0288202-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-049347
- JSON: https://secwatch.observer/filing/0001213900-26-049347.json
- Plain text: https://secwatch.observer/filing/0001213900-26-049347.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.